InvestSMART

Epiminder Limited (ASX:EPI)

ALERT: Price-sensitive ASX Announcement for EPI
Current share price for EPI : $0.345 -0.515 (-59.88%)+
Announcement
Release
25 Feb 2026 8:14AM
Price at Release
$0.860
Full Release
download
Summary
Epiminder Limited, an Australian medical device company, released its interim financial results for the first half of the financial year 2026, ending December 31, 2025. Key developments include a successful capital raise of $125 million and the first implant of the Minder device in the US at the University of Pennsylvania. The company is progressing with its DETECT program across nine US medical centers and aims to implant 210 patients by the end of 1H FY27. The development of the next-generation Minder product, G1, is on track for completion by FY27. Epiminder confirms it has adequate cash resources to support these initiatives through 2028. The outlook for the second half of FY26 anticipates a net cash outflow of approximately $20 million, contingent on the pace of patient enrollments and implantations.
Key Points
  • Epiminder Limited announced 1H FY26 interim financial results.
  • Successfully raised $125 million in capital on December 1, 2025.
  • First US Minder device implant performed at the University of Pennsylvania.
  • The DETECT program has nine US medical centers enrolled.
  • 210 patient target for Minder implants by the end of 1H FY27.
  • Next-generation Minder product, G1, on track for FY27 completion.
  • Sufficient cash resources to fund operations through 2028.
  • Expected net cash outflow of approximately $20 million in 2H FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.